Core Viewpoint - Zhejiang Jianfeng Group's subsidiary, Jianfeng Pharmaceutical, has received approval for the listing of the chemical raw material drug, Empagliflozin, indicating compliance with national standards for raw material drug evaluation and enabling sales in the domestic market, which will help expand the subsidiary's business scope [2][5]. Group 1: Drug Approval and Details - The chemical raw material drug approved is Empagliflozin, with a packaging specification of 10kg per barrel, and the approval notification number is 2025YS00624 [2][3]. - The approval is valid until July 24, 2030, and the registration standard number is YBY66992025 [3]. Group 2: Drug Development and Investment - Empagliflozin is an SGLT2 inhibitor used as an adjunct treatment for improving blood sugar control in adult patients with type II diabetes, functioning by blocking glucose reabsorption in the kidneys [3][4]. - The total investment in the development of the Empagliflozin raw material project is approximately RMB 8.8769 million [4]. Group 3: Impact on the Company - The approval of Empagliflozin signifies that Jianfeng Pharmaceutical has the necessary production capabilities, which will facilitate the expansion of its business in the pharmaceutical sector [5].

Group 1 - The core announcement is that Zhejiang Jianfeng Group's subsidiary, Jianfeng Pharmaceutical, has received the approval notice for the listing application of the chemical raw material drug, Empagliflozin, from the National Medical Products Administration [1][2] - Empagliflozin is classified as a sodium-glucose co-transporter 2 (SGLT2) inhibitor, which aids in blood sugar control for adult patients with type II diabetes by blocking glucose reabsorption in the kidneys [2] - The total investment in the research and development of the Empagliflozin raw material project is approximately RMB 8.8769 million [2] Group 2 - The approval indicates that the raw material drug meets the national technical standards for raw material drug review, allowing it to be sold in the domestic market, which will help expand the subsidiary's business scope [3] - The approval notice is valid until July 24, 2030, and the production facility is located in Jinhua City, Zhejiang Province [2]

证券日报网讯 7月29日晚间，尖峰集团发布公告称，近日，公司的全资子公司浙江尖峰药业有限公司收 到国家药品监督管理局关于化学原料药恩格列净的《化学原料药上市申请批准通知书》（通知书编号： 2025YS00624）。 （文章来源：证券日报） ...

Core Viewpoint - Jianfeng Group's subsidiary, Zhejiang Jianfeng Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the marketing application of the chemical raw material drug Empagliflozin, indicating a significant advancement in the company's product portfolio and potential market opportunities in diabetes treatment [1]. Group 1: Company Developments - The approval notification for Empagliflozin is identified by the document number 2025YS00624, marking a key regulatory milestone for the company [1]. - Empagliflozin is classified as a sodium-glucose co-transporter 2 (SGLT2) inhibitor, which aids in blood sugar control for adult patients with type II diabetes when combined with exercise and diet [1]. - The drug functions by blocking the reabsorption of glucose in the kidneys, leading to the excretion of excess glucose and thereby lowering blood sugar levels, independent of β-cell function and insulin resistance [1]. Group 2: Industry Context - As of the announcement date, there are 28 companies listed on the CDE raw and auxiliary package registration information platform with an "A" status for Empagliflozin, including Jiangsu Hengrui Medicine Co., Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. [1].

Core Viewpoint - The announcement indicates that Jianfeng Group's subsidiary, Zhejiang Jianfeng Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the marketing application of the chemical raw material drug Canagliflozin, which is a SGLT2 inhibitor used for improving blood sugar control in adults with type II diabetes [1]. Group 1 - Jianfeng Pharmaceutical has received the approval notice for Canagliflozin, with the notification number 2025YS00624 [1]. - Canagliflozin functions by blocking glucose reabsorption in the kidneys, leading to reduced blood sugar levels, and its efficacy is independent of β-cell function and insulin resistance [1]. - As of the date of the announcement, there are 28 companies listed with an "A" status on the CDE raw and auxiliary package registration information platform, including Jiangsu Hengrui Medicine Co., Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. [1].

证券代码：600668 证券简称：尖峰集团 编号：临 2025-035 浙江尖峰集团股份有限公司 关于子公司获得化学原料药上市申请批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 近日，浙江尖峰集团股份有限公司（以下简称"本公司"）的全资子公司浙江 尖峰药业有限公司（以下简称"尖峰药业"）收到国家药品监督管理局关于化学原 料药恩格列净的《化学原料药上市申请批准通知书》（通知书编号：2025YS00624）， 现将相关情况公告如下： 一、化学原料药的基本情况 化学原料药名称：恩格列净 包装规格：10kg/桶 通知书编号：2025YS00624 化学原料药注册标准编号：YBY66992025 生产企业名称：浙江尖峰药业有限公司 生产企业地址：浙江省金华市婺城区白汤下线高畈段 58 号 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 1 本次尖峰药业获得化学原料药恩格列净的《化学原料药上市申请批准通 知书》，表明该原料药已符合国家相关原料药审评技术标准，可在国内 市场进行销售 ...

Core Viewpoint - Jianfeng Group's subsidiary, Zhejiang Jianfeng Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the marketing application of the chemical raw material drug, Empagliflozin, which is an SGLT2 inhibitor used as an adjunct treatment for blood sugar control in adult patients with type II diabetes [1] Group 1 - Empagliflozin functions by blocking the reabsorption of glucose in the kidneys, leading to the excretion of excess glucose and thereby lowering blood sugar levels [1] - The glucose-lowering effect of Empagliflozin does not depend on β-cell function and insulin resistance [1] - As of the announcement date, there are 28 companies listed on the CDE raw and auxiliary materials registration information platform with status "A," including Jiangsu Hengrui Medicine Co., Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. [1]

Core Viewpoint - Jianfeng Group's subsidiary, Jianfeng Pharmaceutical, has received approval from the National Medical Products Administration for the marketing of the chemical raw material drug, Empagliflozin, which meets national technical standards for raw material drug review and can now be sold in the domestic market, aiding in business expansion [1] Summary by Categories Company Developments - Jianfeng Pharmaceutical has been granted a marketing approval for Empagliflozin, indicating a significant step in expanding its product offerings [1] Industry Context - The approval of Empagliflozin aligns with the high-tech, high-risk, and high-value characteristics of pharmaceutical products, which are subject to fluctuations due to national policies and market environment changes, highlighting the inherent uncertainties in the industry [1]

Core Viewpoint - A governance initiative against "involution" is gaining momentum in various traditional industries in China, with the Ministry of Industry and Information Technology implementing a new round of growth stabilization plans for ten key industries, including steel, non-ferrous metals, petrochemicals, and building materials [1] Group 1: Industry Response - The steel, non-ferrous metals, and building materials industries are responding quickly with production cuts, indicating a proactive approach to the new policies [1] - The policies aim to eliminate ineffective supply and enhance industry concentration, suggesting a better development environment for quality enterprises [2] Group 2: Structural Opportunities - The steel industry is expected to benefit significantly from high-barrier, high-value-added special steel due to the trend of high-quality economic development and new productivity [2] - In the non-ferrous metals sector, the implementation of policies is anticipated to optimize supply structure and improve efficiency across the industry chain, leading to a mid-term recovery in capacity profits [2] - The building materials industry is poised to benefit from ongoing favorable real estate policies, with leading companies expected to achieve sustained growth through channel optimization and product diversification [2] Group 3: Market Performance - Market enthusiasm has surged, with 68 stocks in the steel, non-ferrous metals, and building materials sectors projected to see a year-on-year net profit increase in the first half of 2025, including 22 companies expected to turn losses into profits [3] - Notable profit growth is reported for companies like Sanhe Pile and Northern Rare Earth, with Sanhe Pile's net profit expected to increase by 30.91 to 38.89 times, driven by product matrix richness and cost control [3] Group 4: Capital Inflow - The improvement in performance has led to a significant influx of market capital, with the aforementioned 68 stocks averaging a 15.82% increase in July, and some stocks like Liugang Co. and Shenghe Resources seeing cumulative gains exceeding 40% [5] - As of July 23, 23 stocks had rolling P/E ratios below 30, indicating perceived undervaluation, with companies like Huaxin Cement and Zijin Mining in the 10-15 P/E range [5] - Financing activities have also increased, with several stocks, including Zijin Mining and Huayou Cobalt, seeing net purchases exceeding 100 million yuan since July [5]

Group 1 - The Yarlung Tsangpo River downstream hydropower project has officially commenced with a total investment of approximately 1.2 trillion yuan, aiming to build five tiered power stations primarily for electricity transmission and local consumption in Tibet [1] - The Ministry of Industry and Information Technology (MIIT) plans to accelerate the development of biomanufacturing and low-altitude industries, while promoting innovation in future industries such as humanoid robots and brain-computer interfaces [2][3] - The MIIT and the National Development and Reform Commission (NDRC) are set to issue work plans to stabilize growth in key industries including steel, non-ferrous metals, petrochemicals, and building materials [2][3] Group 2 - The U.S. Department of Commerce has imposed a preliminary anti-dumping duty of 93.5% on Chinese imported anode-grade graphite, citing unfair subsidies [5] - The State Administration for Market Regulation has urged major platform companies like Ele.me, Meituan, and JD.com to standardize promotional activities and foster a healthy competitive environment in the food service industry [6] - A meeting was held to discuss the regulation of the new energy vehicle industry, focusing on enhancing supervision and monitoring product prices and quality [8] Group 3 - The China Iron and Steel Association has proposed a new mechanism for capacity governance to prevent overcapacity risks in the steel industry and to eliminate irrational competition [10] - Yu Shu Technology has initiated its listing guidance, with its controlling shareholder holding approximately 34.76% of the company's shares [11] - Multiple provinces are planning to establish companies to develop local cultural creative Moutai liquor, with participation from distributors based on their allocation of Moutai products [12] Group 4 - As of July 18, 1551 A-share listed companies have released performance forecasts for the first half of 2025, with 26 companies expecting a net profit increase of over 1000% year-on-year [14] - Longhua Automobile reported a net profit of 6.337 billion yuan for the first half of the year, reflecting a year-on-year decline of 10.22% [19] - The major shareholder of Hongbaoli plans to reduce its stake by up to 2% [20]